Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Rating of "Hold" from Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have been assigned an average recommendation of "Hold" from the eight brokerages that are currently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $4.78.

Several equities analysts have recently commented on the stock. Jefferies Financial Group restated a "hold" rating and issued a $0.70 price objective (down from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday. Wells Fargo & Company restated an "equal weight" rating and set a $1.00 target price (down from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday. Leerink Partners lowered their price objective on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a research note on Monday. Citizens Jmp lowered shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday. Finally, JMP Securities dropped their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a research note on Thursday, January 30th.

Ironwood Pharmaceuticals Price Performance

IRWD traded down $0.05 during trading hours on Friday, reaching $0.67. The company's stock had a trading volume of 396,337 shares, compared to its average volume of 2,539,127. The business's 50-day moving average is $1.50 and its 200-day moving average is $3.08. The stock has a market cap of $108.25 million, a PE ratio of -22.30 and a beta of 0.30. Ironwood Pharmaceuticals has a fifty-two week low of $0.59 and a fifty-two week high of $8.45.

Remove Ads

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million. Analysts expect that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

Insiders Place Their Bets

In related news, CMO Michael Shetzline sold 41,269 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Thomas A. Mccourt sold 139,064 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the transaction, the chief executive officer now owns 1,160,634 shares in the company, valued at $2,042,715.84. The trade was a 10.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 192,381 shares of company stock valued at $338,591 over the last quarter. Company insiders own 12.90% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Pacer Advisors Inc. increased its stake in Ironwood Pharmaceuticals by 4.0% during the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock worth $51,967,000 after buying an additional 450,949 shares during the period. State Street Corp increased its holdings in Ironwood Pharmaceuticals by 7.3% during the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company's stock worth $40,870,000 after purchasing an additional 677,024 shares during the last quarter. FMR LLC raised its position in shares of Ironwood Pharmaceuticals by 25.1% in the 3rd quarter. FMR LLC now owns 169,681 shares of the biotechnology company's stock valued at $699,000 after purchasing an additional 34,089 shares in the last quarter. Jane Street Group LLC grew its position in shares of Ironwood Pharmaceuticals by 102.7% during the third quarter. Jane Street Group LLC now owns 323,638 shares of the biotechnology company's stock worth $1,333,000 after buying an additional 164,006 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Ironwood Pharmaceuticals by 4.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company's stock worth $8,786,000 after buying an additional 78,969 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.